ARASENS trial: Darolutamide improves survival in metastatic hormone-sensitive prostate cancer

“I think results from this study introduce a new standard of care for patients with metastatic hormone-sensitive prostate cancer, where we clearly need to do better than what we're doing today, since the sequence of therapy seems to be less effective than hitting them hard upfront,” says Fred Saad, MD, FRCS.

In this video, Fred Saad, MD, FRCS, discusses the background and findings of the study, “Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Saad is a professor and chief of urology, director of GU oncology, and Raymond Garneau Chair in prostate cancer at the University of Montreal Hospital Center (CHUM), as well as the director of prostate cancer research at the Montreal Cancer Institute/CRCHUM in Quebec.